Search results
GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology
Reuters via Yahoo Finance· 11 hours ago(Reuters) -GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing...
Pfizer vs Moderna battle over COVID vaccine patents begins in UK
KFGO· 2 days agoBy Sam Tobin LONDON (Reuters) - Pfizer and BioNTech asked a London court to revoke rival Moderna's...
Analysts Expect Moderna's First-Quarter Sales To Plummet 95% — Is Moderna Stock A Sell?
Investor's Business Daily· 1 day agoModerna is rivaling vaccine makers Pfizer and Novavax. Still, the market for Covid boosters is...
...BioNTech in London Patent Battle over Covid-19 Vaccines In Legal Showdown - Moderna...
Benzinga· 2 days agoModerna Inc. MRNA is set to clash with Pfizer Inc. PFE and BioNTech SE BNTX in a pivotal London...
Rival Covid-19 jab developers face off in High Court patent trial
Press Association News via AOL· 2 days agoMr Mitcheson said that “it is clear that even on Moderna’s case the difference between the prior art...
COVID Vaccine Study Finds Small Signal of Seizure Risk in Young Kids
MedPage Today· 2 days agoResearchers also detected a statistical signal for seizures after vaccination with the BNT162b2 ...
Uveitis History Linked to Recurrence After COVID Vaccination
MedPage Today· 19 hours ago(HR 2.07, 95% CI 1.40-3.07). "These findings suggest that there was an elevated risk of uveitis...
Cerity Partners LLC Grows Stock Position in Moderna, Inc. (NASDAQ:MRNA)
ETF DAILY NEWS· 19 hours agoCerity Partners LLC increased its position in shares of Moderna, Inc. (NASDAQ:MRNA – Free Report) by 106.6% during the 4th quarter, according to the company in its most recent ...
COVID Shot Boosts Mucosal Immunity in Previously Infected People
MedPage Today· 3 days agoOnly 'traces' of spike-specific salivary antibodies found in vaccinated SARS-CoV-2-naive people
Cwm LLC Has $11.77 Million Holdings in Moderna, Inc. (NASDAQ:MRNA)
ETF DAILY NEWS· 4 days agoCwm LLC lifted its holdings in shares of Moderna, Inc. (NASDAQ:MRNA – Free Report) by 27.1% during the fourth quarter, according to the company in its most recent Form 13F ...